Showing results (181-190 of 315) with videos related to

Sort By:
Pageof 32
Circulation. Heart Failure|April 7, 2025
Effect of a Meal on Invasive Hemodynamics and Plasma Incretin Levels in Patients With Heart FailureTania Deis, Kasper Rossing, Mads Ersbøll, et al.
The Journal of Nutrition|February 8, 2022
The Role of D-allulose and Erythritol on the Activity of the Gut Sweet Taste Receptor and Gastrointestinal Satiation Hormone Release in Humans: A Randomized, Controlled TrialFabienne Teysseire, Valentine Bordier, Aleksandra Budzinska, et al.
The American Journal of Clinical Nutrition|January 15, 2016
Jejunal feeding is followed by a greater rise in plasma cholecystokinin, peptide YY, glucagon-like peptide 1, and glucagon-like peptide 2 concentrations compared with gastric feeding in vivo in humans: a randomized trialJoanna Luttikhold, Klaske van Norren, Herman Rijna, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|June 15, 2013
Glucagon-like peptide-2 induces rapid digestive adaptation following intestinal resection in preterm neonatesAndreas Vegge, Thomas Thymann, Pernille Lund, et al.
Frontiers in Immunology|December 27, 2021
Glucagon-Like Peptide-1 Is Associated With Systemic Inflammation in Pediatric Patients Treated With Hematopoietic Stem Cell TransplantationMaria Ebbesen, Hannelouise Kissow, Bolette Hartmann, et al.
JPEN. Journal of Parenteral and Enteral Nutrition|January 24, 2015
Provision of Amniotic Fluid During Parenteral Nutrition Increases Weight Gain With Limited Effects on Gut Structure, Function, Immunity, and Microbiology in Newborn Preterm PigsMette Viberg Østergaard, Rene Liang Shen, Ann Cathrine Findal Støy, et al.
Diabetes Care|October 11, 2023
Dasiglucagon Treatment for Postprandial Hypoglycemia After Gastric Bypass: A Randomized, Double-Blind, Placebo-Controlled TrialCasper K Nielsen, Caroline C Øhrstrøm, Inas J K Houji, et al.
Diabetes, Obesity & Metabolism|September 5, 2020
Dose-dependent efficacy of the glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist GIP(3-30)NH2 on GIP actions in humansLaerke Smidt Gasbjerg, Emilie J Bari, Signe Stensen, et al.
European Journal of Endocrinology|January 18, 2023
The naturally occurring GIP(1-30)NH2 is a GIP receptor agonist in humansLiva S L Krogh, Kristine Henriksen, Signe Stensen, et al.
Diabetes|March 30, 2026
LEAP2 Reduces Ad Libitum Food Intake and Attenuates Postprandial Glucose Excursions in Men With ObesityAnders Englund, Andreas H Lange, Christoffer A Hagemann, et al.
Pageof 32